PRA Health Sciences, Salt Lake City, UT, USA.
Inspirion Delivery Sciences LLC, Morristown, NJ, USA.
Adv Ther. 2019 Jul;36(7):1730-1740. doi: 10.1007/s12325-019-00963-0. Epub 2019 May 7.
Oxycodone ARIR is a novel oral, abuse-deterrent, immediate-release (IR) formulation with physical and chemical properties that deter misuse and abuse by non-oral routes. In this single-dose pharmacokinetic study, we assessed the relative bioavailability of oxycodone for Oxycodone ARIR and IR oxycodone, and the effect of food on Oxycodone ARIR following oral administration.
This open-label, randomized study in healthy adults compared the relative bioavailability of Oxycodone ARIR 30 mg to IR oxycodone 30 mg under fasted conditions, and Oxycodone ARIR under fed versus fasted conditions. Pharmacokinetic parameters included area under the concentration-time curve from time 0 to the last measured concentration (AUC) and the maximum oxycodone plasma concentration (C). Equivalence was determined using an analysis of variance of the least-squares means.
Fifty-eight subjects completed the study. Under fasted conditions, AUC was 4% lower (90% CI 92.5-98.7%) and mean C was 14% lower (90% CI 78.8-94.3%) for Oxycodone ARIR versus IR oxycodone. AUC was 23% higher (90% CI 119.1-127.0%) and mean C was higher (90% CI 108.6-129.4%) when Oxycodone ARIR was administered in the fed versus fasted state. Common adverse events included nausea, headache, and dizziness.
In this single-dose pharmacokinetic evaluation, fasted Oxycodone ARIR 30 mg had similar bioavailability to and is expected to have the same efficacy and safety profile as IR oxycodone. When administered in the fed state, pharmacokinetic parameters were slightly higher; however, these differences were considered not clinically meaningful and show that Oxycodone ARIR can be administered with or without food.
This study was funded by Inspirion Delivery Sciences, LLC. Daiichi Sankyo, Inc. funded the journal's article processing charges and open access fee. Plain language summary available for this article.
奥施康定 ARIR 是一种新型的口服、防滥用、即时释放(IR)制剂,具有阻止通过非口服途径滥用和误用的物理和化学性质。在这项单次剂量药代动力学研究中,我们评估了奥施康定 ARIR 和 IR 奥施康定的相对生物利用度,以及口服奥施康定 ARIR 后食物对其的影响。
这项在健康成年人中进行的开放标签、随机研究比较了奥施康定 ARIR 30 毫克与 IR 奥施康定 30 毫克在禁食条件下以及奥施康定 ARIR 在进食与禁食条件下的相对生物利用度。药代动力学参数包括从 0 时间到最后测量浓度的浓度-时间曲线下面积(AUC)和最大奥施康定血浆浓度(C)。使用最小二乘均值的方差分析来确定等效性。
58 名受试者完成了这项研究。在禁食条件下,奥施康定 ARIR 与 IR 奥施康定相比,AUC 低 4%(90%CI 92.5-98.7%),C 均值低 14%(90%CI 78.8-94.3%)。奥施康定 ARIR 在进食状态下给药时,AUC 高 23%(90%CI 119.1-127.0%),C 均值高(90%CI 108.6-129.4%)。常见的不良反应包括恶心、头痛和头晕。
在这项单次剂量药代动力学评估中,奥施康定 ARIR 30 毫克在禁食状态下具有相似的生物利用度,预计与 IR 奥施康定具有相同的疗效和安全性。当在进食状态下给药时,药代动力学参数略有升高;然而,这些差异被认为没有临床意义,表明奥施康定 ARIR 可以在有或没有食物的情况下给药。
这项研究由 Inspirion Delivery Sciences,LLC 资助。第一三共株式会社资助了本研究的杂志文章处理费和开放获取费。本文提供了通俗易懂的摘要。